摘要
目的观察应用益肾通脉方治疗急性脑梗死的临床疗效。方法将160例急性脑梗死证属肾虚血瘀痰阻的患者随机分为治疗组和对照组各80例,治疗组在常规西药治疗基础上给予益肾通脉方,对照组给予常规西药治疗。疗程4周。观察治疗前及治疗后2周、8周、12周美国国立卫生研究院卒中量表(NIHSS)评分,血清神经元特异性烯醇化酶(NSE)含量,治疗后4周、12周Barthel评分(BI)变化,以及治疗前后临床疗效评定。结果总有效率治疗组为96.25%,对照组为82.50%,治疗组优于对照组(P<0.05)。治疗组NIHSS评分、NSE水平低于对照组(P<0.05),BI评分高于对照组(P<0.05)。结论益肾通脉方治疗证属肾虚血瘀痰阻型急性脑梗死疗效优。
Objective Clinical observation of Yishen Tongmai prescription in treatment of acute cerebral infarction. Methods 160 cases of acute cerebral infarction in patients with kidney deficiency syndrome and blood stasis phlegm randomly divided into treatment group and control group,.80 cases each. The treatment group received Yishen Tongmai prescription and conventional western medicine. The control group received conventional western medicine. 4 weeks. Observed before treatment and after treatment for 2 weeks,8 weeks and 12 week of National Institutes of Health Stroke Scale（NIHSS）score,serum neuron-specific enolase（NSE） content,after 4 weeks and 12 weeks of Barthel score（BI）changes before and after treatment and clinical efficacy evaluation. Results The total efficiency of the treatment group was 96.25%,82.50% in the control group,the treatment group was higher than the control group（P〈0.05）. NIHSS score,NSE levels were significantly lower than the control group（P〈0.05）, BI score was significantly higher（P〈0.05）,there are significant differences. Conclusion Yishen Tongmai prescription in the treatment of acute cerebral infarction is significant.
出处
《中国卫生标准管理》
2016年第6期125-127,共3页
China Health Standard Management
基金
泰安市科技发展计划项目
项目编号(20123076)
